Esteve Labs   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Barcelona Spain (1929)

Organization Overview

First Clinical Trial
2004
NCT00728715
First Marketed Drug
2006
polyethylene glycol 3350 (colyte)
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

BRECKENRIDGE | BRECKENRIDGE PHARM | Breckenridge Pharmaceuticals | BRECKENRIDGE PHARMS | Esteve Labs (Grant) | Laboratorios del Dr. Esteve, S.A. | Laboratorios del Dr. ESTEVE, S.A.U